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a b s t r a c t 
A higher chronic expansion of effector cytotoxic CD8 + DR + T-lymphocytes has been reported in common 
variable immunodeﬁciency (CVID) patients with complications such as splenomegaly, autoimmune disease 
and / or granulomatous disease. In order to document the features associated with this T cell activation 
involving the CD8 + T-compartment, we examined the diversity of the alpha / beta TCR repertoire of the 
patient’s CD8 + T-lymphocytes using the qualitative analysis of the CDR3 lengths (Immunoscope). 
Ten CIVD patients were enrolled in this study, four without complications (Group 1), six with complications 
(Group 2). All patients exhibited non-gaussian altered CDR3 length distributions, albeit to different extent 
within the different V β families. CVID patients with activated CD8 + T-cells show a reduction of their TCR 
repertoire diversity which is more severe in patients with complications. Viral reactivations such as CMV are 
suspected to be part of the mechanisms underlying immunosenescence. 
c © 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.. Introduction 
Common variable immunodeﬁciency (CVID) is a highly heteroge- 
eous group of B cell-deﬁciency syndromes all characterized by de- 
ective antibody production and recurrent sino-pulmonary bacterial 
nfections [ 1 , 2 ]. Other important clinical features are also observed 
n about 25% of patients, including lymphadenopathy, splenomegaly, 
ranulomatosis and / or autoimmune diseases [ 1 –3 ]. The recently pro- 
osed classiﬁcations of CVID patients based on ﬂow cytometric quan- 
iﬁcation of class-switched memory and immature blood B-cells [ 4 ], 
lthough useful for patients caring, is insufﬁcient as many patients 
lso have circulating immunophenotypic T-cell abnormalities, par- 
icularly signiﬁcantly elevated CD8 + T-cells expressing the activa- 
ion marker HLA-DR [ 5 ]. We reported on an expansion of CD8 + HLA- 
R + T-lymphocytes with an effector phenotype in a subset of CVID 
atients with splenomegaly, lymphoid hyperplasia and / or granulo- 
atosis [ 5 ]. To gain further insight into the nature of this expansion      
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Open access under CC BY-NC-ND licof CD8 + T-lymphocytes in this group of CVID patients, we exam- 
ined their αβTCR repertoire assessing the CDR3 length polymorphism 
(CDR3-LP) of their CD8 + T-lymphocytes providing a highly sensitive 
detection of overrepresented CD8 + T-cells. 
2. Materials and methods 
2.1. Patients 
Among the 10 CVID patients enrolled in this study, six were men 
and four were females. All patients had been diagnosed as having CVID 
based on recurrent bacterial infections associated with hypogamma- 
globulinemia (serum IgG and IgA and / or IgM ≥ 2 standard deviations 
(SD) below the normal mean), conﬁrmed on two occasions 12 weeks 
apart, while all secondary causes have been excluded [ 6 ]. At the time 
of the evaluation, none of the patients had any sign of acute infec- 
tion. A single CDR3 length polymorphism evaluation was carried out 
per patient between 6 years and 30 years following diagnosis, and 
clinical data available at this time point were collected. All partic- 
ipants gave their written informed consent. All patients, but one, 
were receiving substitution therapy with intravenous immunoglob- 
ulins (IVIgs) preparations. Splenomegaly was diagnosed when the 
spleen was > 13 cm long on computed tomography scan. Granuloma- 
tous disease and lymphoid hyperplasia were diagnosed from lymph- 
node biopsies and / or splenectomy. Immune thrombocytopenia ( ITP) 
was deﬁned according to the published standardized international ense.
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Fig. 1. Average Immunoscope proﬁle obtained from the T cell repertoire analysis of 
13 healthy individuals. For technical details, see Section 2 . The distribution of TCR β
CDR3 lengths (peak proﬁle representation) for each V β family is a typical Gaussian- 
like proﬁle which characterizes the polyclonal response usually observed in healthy 
volunteers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 criteria [ 7 ]. 
2.2. Flow cytometric analysis 
Whole blood was collected in tubes containing sodium
ethylenediaminetetraacetate (Becton-Dickinson, Le Pont de Claix,
France). PBL from CVID pts were analyzed by 4-color ﬂow cytom-
etry (FacsCalibur, Becton-Dickinson, Moutain View, CA). For patients
given replacement therapy, blood samples were collected just before
the IVIgs infusion. Flow cytometric analyses for patients and controls
were performed within the next 24 h following blood withdrawal.
We used speciﬁc antibodies, conjugated to ﬂuorescein isothiocyanate,
phycoerythrin (PE), peridinin chlorophyll protein or allophycocyanin,
directed against the following surface markers: CD3, CD8, CD4, CD45,
CD57, HLA-DR, CD19, CD27 and sIgD (all from Beckman-Coulter, Mar-
seille, France). IgG1 or IgG2a isotypes were used as isotypic controls.
For intracellular labelling of granzyme B and perforin, PBL were ﬁrst
incubated with anti-CD3, -CD8 and HLA-DR for 30 min in order to
tag cell surface molecules. Cells were then resuspended in 1 × ﬁ-
nal Permeaﬁx (BDBiosciences, Pont de Claix, France) for 30 min at
room temperature before labelling with either anti-granzyme B-PE,
anti-perforin-PE or a PE-conjugated isotypic control. Lymphocytes
were gated according to their forward and side scatter (only for CD3 /
CD8 / HLA-DR / perforin or granzyme B panels) and highest expression
of CD45 characteristics otherwise. For the B-cell phenotyping, pa-
tients were classiﬁed according the recent EURO-class system which
is based on the absence or the presence of circulating B lympho-
cytes (B − group: CD19 + ≤ 1%; B + group: CD19 + > 1% of total lym-
phocytes) [ 4 ]. Within the B + group, patients are classiﬁed according
to the proportion of switched memory B (smB) cells (smB − group:
IgD −CD27 + / CD19 + ≤ 2%; smB + group: IgD −CD27 + / CD19 + >
2%). For all patients, ﬂow cytometric analyses have been carried out
repeatedly every 6 months for at least a period of time of 3 years
(maximum 6 years) before the repertoire assessment. 2.3. Blood samples, RNA extraction and analysis of CDR3 length 
Thirty milliliters of blood were collected by venopuncture and
anti-coagulated with sodium EDTA. Peripheral blood mononuclear
cells (PBMC) were recovered after a Ficoll-Hypaque gradient (Euro-
bio, Les Ulis, France) and CD8 + T-cells sorted using MACS CD8 mi-
crobeads (Miltenyi, Bergisch Gladbach, Germany). After washing, 2
× 10 7 CD8 + T-cells were added with Trizol ® reagent (Invitrogen TM ,
Life Technologies, CA, USA) for RNA extraction according to manu-
facturer’s instructions. The RNA concentration for each sample was
determined by optical density measurement, and RNA quality was
checked by running samples on a 1% agarose gel. Two 2 μg of RNA
were reverse transcribed using an Invitrogen cDNA synthesis kit
(Boeringher Mannheim, Indianapolis, IN) and diluted to a ﬁnal vol-
ume of 100 μL. Complementary DNAs were ampliﬁed by PCR using
a C β primer and one of the 26 speciﬁc V βprimers. The ampliﬁca-
tions were performed in a 9600 Perkin-Elmer thermocycler (Applied
Biosystems, Foster City, CA, USA) as previously described [ 8 ]. Brieﬂy,
each ampliﬁcation product was used for an elongation reaction us-
ing a dye-labeled C β primer, then heat-denatured, loaded onto a 6%
acrylamide-8 M urea gel and electrophoresed for 5 h using an Applied
Biosystems 373A DNA sequencer (Perkin-Elmer 
®
). 
2.4. TCR repertoire analysis and statistical analysis 
Diversity and T-cell selection in the CD8 + compartment were as-
sessed by analysis of TCR ( β chain) usage biases. Analysis of CDR3-LD
was performed using Immunoscope 
®
software [ 9 ]. The percentage
of CDR3-LD alteration for each V β family and a global percentage of
CDR3-LD alteration for each individual or group were calculated as
described [ 10 ]. The percentage of alteration was deﬁned as the differ-
ence between the frequency of each CDR3 length in the distribution
proﬁle and the control distribution, calculated from the 13 age- and
gender-matched healthy individuals. The global CDR3-LD alteration
is represented as a topview TcLandscape 
®
enabling an easy appraisal
of the ‘qualitative ’ measurement of the CDR3-LD bias (see Figs. 1 and
2). Only CDR3 lengths with an alteration above 30% were taken into
account. The level of V βRNA was measured by real-time quantitative
PCR and expressed as a ratio of a nonregulated or minimally regulated
gene, HPRT. The primers used were especially designed for quantita-
tive PCR as previously described [ 8 ]. The data were displayed as a
three-dimensional TcLandscape 
®
[ 11 –13 ]. Percentages of CDR3-LD
alterations are represented as a color code, from deep blue ( −50%) to
dark red ( + 50%). The X -axis displays the 26 human V β families, the Y -
axis gives the V β/ HPRT ratios and the Z -axis gives the CDR3 lengths.
The color code for the tridimensional TcLandscape 
®
is the same as
that used for the corresponding topview. All T cell-subpopulation
percentages and qualitative (percentage of alteration) values for each
V β family were compared between groups using the non-parametric
Mann Whitney U -test, with signiﬁcance set at p = 0.05, and Statistica
Inc. software (Statsoft, Tucson, AZ). 
2.5. Statistical analysis 
All T cell-subpopulation percentages and qualitative (percentage
of alteration) values for each V β family were compared between
groups using the non-parametric Mann Whitney U -test, with sig-
niﬁcance set at p = 0.05, and Statistica Inc. software (Statsoft, Tucson,
AZ). 
3. Results 
3.1. Patient population 
Among our cohort of 71 CVID pts followed in our Department,
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Fig. 2. Immunoscope analysis of the T cell repertoire in ten CVID patients. For technical details, see section Methods. Pt = Patient. T-cell clonal expansions manifest as a distribution 
skewed by the presence of larger peaks that accumulate above the Gaussian-like background of polyclonal T cells, particularly in CVID patients with granulomatosis (patients 5 
and 7). 
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Table 1 
Summary of the demographic and clinical characteristics of CVID patients. 
Patients no. Age / sex Age at diagnosis 
Infectious 
manifestations a Splenomegaly 
Autoimmune 
diseases b 
Lymphoid 
proliferation 
Granulomatous 
disease 
Group 1 
1 57 / F 38 S, B, An − − −
2 49 / M 26 S, B, P, G − − − −
3 32 / F 21 S, An, B − − − −
4 30 / F 27 G, P, digestive 
infections 
( Salmonella ), 
Herpes 
− − − −
Group 2 
5 61 / F 52 S, P, B, urinary 
infections 
+ − + + 
6 37 / M 31 S, G, B, P, Sep + − + −
7 75 / M 68 S, B, P + − − + 
8 43 / M 27 An, S, B, P + + (ITP) + −
9 54 / M 24 S, B, P − − + −
10 39 / M 30 S, B, P + + (ITP) + −
Patients in Group 2 were diagnosed at a later age than Group 1 (median values: 30.5 years versus 26.5 years, respectively, not statistically signiﬁcant). Complications were present 
in all patients in Group 2 at diagnosis and, in four of them, they revealed CVID. At the time of the study, all patients, except patients 7, received IVIgs treatment every 3 or 4 weeks, 
and all had a residual serum IgG level > 8 g / l. 
a An: angina; B: bronchitis; G: giardiasis infection; P: pneumonia; S: sinusitis; and Sep: septicemia. 
b ITP: idiopathic thrombocytopenic purpura. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 we studied the 10 patients for whom we had an extended follow-up
time and repeated lymphocytes phenotyping in the history of their
disease. Their median ages were 46 years (range: 30–75 years) and
their median follow-up were 9 years (minimum 6 years, maximum
30 years). Their individual clinical characteristics are summarized in
Table 1 . Recurrent bacterial respiratory tract infections were common
to all CVID patients but among them, six (pts 5–10) had other clin-
ical manifestations including autoimmune diseases (2 ITP, patients
8 and 10), chronic granulomatous disease (patients 5 and 7) and / or
organomegaly caused by lymphoid hyperplasia (patients 5, 6, 8, 9
and 10). Patients were then divided into two groups: the Group 1
including those for which the only clinical features noted have been
sino-pulmonary bacterial infections before IVIg substitution ( n = 4,
patients 1–4) and the Group 2 gathering the patients with other ad-
ditional clinical complications ( n = 6, patients 5–10). 
Patients in Group 2 were diagnosed at a later age than Group 1
(median values: 30.5 years versus 26.5 years, respectively, not sta-
tistically signiﬁcant). Complications were present in all patients in
Group 2 at diagnosis and, in four of them, they revealed CVID. At the
time of the study, all patients, except patient 7, received IVIgs treat-
ment every 3 or 4 weeks, and all had a residual serum IgG level > 8 g /
l. 
3.2. Activation of a high proportion of CD8 + T lymphocytes in CVID 
patients 
Phenotypic characteristics of peripheral circulating lymphocytes
in the 10 CVID patients are reported in Table 2 . All had a signiﬁcant
percentage of detectable circulating B cells (CD19 + > 1% of total lym-
phocytes) and were then classiﬁed in the B + group according to the
EURO-class system. Among them, 4 CVID patients belonged to the
smB − group (% of CD19 + expressing CD27 but sIgD − ≤2% of B cells),
and 6 belonged to the smB + group (% of CD19 + expressing CD27
but sIgD − > 2%). We did not observe any correlation between the
EURO-Class and the two groups of patients based on the occurrence
of clinical complications probably due to the small sample of our
population. Three patients had a T-cell lymphocytosis (patients 5–7),
which could be explained primarily by an expansion of the CD8 + T-
compartment. Three others (patients 4, 9 and 10) had a CD4 + T-cell
lymphopenia between 300 and 500 / μl. Patient 4 showed a CD8 + T-
cell lymphopenia of unknown origin. All Group 2 patients displayed adiminished CD4 + / CD8 + ratio, either because of CD4 + lymphopenia
or / and CD8 + lymphocytosis, while all patients of the Group 1 had a
normal ratio CD4 + / CD8 + . 
As shown in Table 2 , Group 2 patients were characterized by
a statistically signiﬁcant increase in their percentages of HLA-DR-
expressing CD3 + T-cells when compared to Group 1 patients ( p =
0.009). This activated phenotype was principally contributed by the
CD3 + CD8 + T-lymphocytes ( p = 0.009) and marginally by the CD3 + 
CD4 + T-cells ( p = 0.06). This difference could be partially due to
a signiﬁcantly higher number and percentages of circulating CD3 + 
CD8 + T-cells in the Group 2 compared with the Group 1 ( p = 0.009),
whereas we did not notice any difference regarding the number and
the percentages of circulating CD3 + or CD3 + CD4 + T-cells between
the 2 groups. We observed a strict correlation between the number of
circulating CD3 + CD8 + T-cells and the percentage of circulating HLA-
DR-expressing CD8 + T-cells (Spearman test: r = 0.85, p = 0.001). The
ratio CD4 + / CD8 + was very different between the two groups (me-
dian values: 1.68 in the Group 1 versus 0.47 in the Group 2, p = 0.009)
which always reﬂected the CD8 + T-cell expansion and not a CD4 + 
lymphopenia. Moreover, when we considered the activation status
within each circulating lymphocytes subsets, the CD8 + T-cells were
still signiﬁcantly more activated in the Group 2 than in the Group 1
( p = 0.009), whereas no difference was observed in the CD4 + T-cells
between the 2 groups ( p = 0.06). 
We also conﬁrmed our previous results that median percentages of
intracellular expression of perforin or granzyme B in peripheral blood
CD8 + DR + T-cells were signiﬁcantly more elevated in the Group 2
linking the presence of complications in these patients to an acti-
vated CD8 + T-lymphocytes effector (CCR7 − and CD45RA + ) cytotoxic
phenotype (data not shown) [ 5 ]. 
This phenotyping proﬁle has been stable for at least the 3 last years
of patients’ follow-up with a maximum follow-up of 6 years. 
3.3. Repertoire analysis of blood CD8 + T cell subsets 
To see whether the activated CD3 + CD8 + T-cells were the result of
a clonal expansion, we undertook their TCR repertoire analysis. Using
the immunoscope method, the distribution of TCR β CDR3 lengths
for each V β is visualized as a series of peaks separated by a distance
of three nucleotides corresponding to in-frame transcripts [ 9 ]. A sin-
gle CDR3-LD evaluation was carried out per patient, and clinical data
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Table 2 
Summary of the immunologic characteristics of CVID patients. 
Pt-1 Pt-2 Pt-3 Pt-4 Pt-5 Pt-6 Pt-7 Pt-8 Pt-9 Pt-10 
Healthy 
controls 
( n = 12) 
Group 1 
( n = 4) 
Group 2 ( n 
= 6) 
% 
CD19 + - 
B 
cells 
14.92 14.87 6.8 11.9 5.12 7.68 5.5 8 5 4.5 11.89 
(8.32–
13.25) 
13.39 
(9.36–
14.9) 
5.31 
(5–7.68) a , b 
CD19 + - 
B 
cells / μl 
299 132 152 99 305 261 268 191 135 82 269 
(211–
338.5) 
142 
(115.5–
225.5) 
226 
(135–268) 
% 
CD19 + 
IgD −
CD27 + - 
B cells 
20.81 3 4.12 5.53 1.8 6.23 1.34 3 0.12 1.87 16.04 
(11.88–
20) 
4.83 
(3.56–
13.17) 
1.83 
(1.34–3) a 
EURO- 
CLASS 
smB + smB + smB + smB + smB − smB + smB − smB + SmB − SmB −
CD3 + -T 
cells 
( / μl) 
1234 1651 1368 622 5112 2871 3572 1166 1203 1324 1530.5 
(1308–
1734) 
1301 
(928–
1509.5) 
2097 
(1203–
3572) 
CD4 + -T 
cells 
( / μl) 
673 1053 726 450 1811 778 701 536 389 396 875 
(753–
1120) 
699.5 
(561.5–
889.5) 
618.5 
(396–778) 
CD8 + -T 
cells 
( / μl) 
494 527 530 141 3072 1967 2773 543 750 906 484 
(413–
595) 
510.5 
(317.5–
528.5) 
1436 (750–
2773) a , c 
CD4 + / 
CD8 + 
ratio 
1.36 1.99 1.36 3.19 0.59 0.40 0.25 0.98 0.52 0.43 1.85 
(1.60–
2.31) 
1.68 
(1.36–
2.59) 
0.475 (0.4–
0.59) a , c 
% 
CD3 + –
DR + -T 
cells 
16.71 2.64 9.76 4.6 59 53.88 46.27 51.96 32.15 26.48 6.90 
(5.40–
8.65) 
7.18 
(3.62–
13.23) 
49.11 
(32.15–
53.88) a , c 
% 
CD4 + –
DR + -T 
cells 
7.5 1.6 6.2 4.4 59 28.78 32.1 41.38 1.8 20.72 2.77 
(2.25–
3.78) 
5.30 (3–
6.85) 
30.44 
(20.72–
41.38) a 
% 
CD8 + –
DR + -T 
cells 
21.03 5.51 10.81 6.1 77.32 65.15 50.95 62.98 40.45 36.46 3.31 
(2.57–
4.94) 
10.68 
(8.32–
15.92) d 
56.96 
(40.45–
65.15) a , c 
% 
CD8 + –
DR + - 
Perforin + 
T cells 
2.69 15 1.64 8 48.91 51.05 56 37.33 19.83 18.67 5.43 
(2.11–
6.75) 
5.34 
(2.16–
11.5) 
43.12 
(19.83–
51.05) a , c 
% 
CD8 + –
DR + - 
Granzyme + 
T cells 
5.20 11 2.52 7 58.95 60.39 66 50.21 24.72 29.87 5.31 
(3.48–
7.62) 
6.1 
(3.86–
9) 
54.58 
(29.87–
60.39) a , c 
For Groups 1 and 2, results are expressed as medians and (25th; 75th percentiles). Comparisons were made with the non-parametric Mann-Whitney U -test. Other between-group 
comparisons were not statistically signiﬁcant. 
a p ≤ 0.001 versus healthy controls. 
b p = 0.03 versus Group I. 
c p ≤ 0.009 versus Group 1. 
d p = 0.0002 versus healthy controls. 
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A percentage of CDR3-LD alteration for each V β family was calcu- 
ated as described (see Table 3 ) [ 11 ]. More was the repertoire biased 
reater was the score for one particular V β family. A biclonal picture such as pt 1 V β8 was granted a score of 90%, whereas the Gaus- 
sian distribution obtained from pt 3 V β11 yielded a score of 7% of 
alteration. When compared to the Group 1, the median percentage 
of CDR3-LD was signiﬁcantly higher in the group of CVID pts with 
complications for the V2 (31.7% versus 17.16%, p = 0.01) and the V5.1 
beta families (30.44% versus 17.97%, p = 0.03). However, recurrence 
of a particular peak was not found among patients .There were no V β
family untouched, nor V β families consistently concerned except the 
two aforementioned. 
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Table 3 
Percentages of CDR3-LD alteration for each V β family calculated as described in Ref. [ 11 ]. 
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Patient 9 Patient 10 
V β 1 32.26 31.76 19.15 34,31 15.24 30.01 23.22 44.89 48,34 24,50 
V β 2 17.64 19.28 9.19 16.69 35.9 23.58 56.76 36.66 27.5 18.85 
V β 3 16.86 55.31 16.84 31.19 76.61 15.14 77.35 9.86 18.95 37.79 
V β 4 50.37 48.15 19.73 33.28 71.84 21.18 17.5 12.37 28.7 33.37 
V β 5.1 21.68 16.98 18.77 17.18 57.88 18.72 37.01 26.01 27.57 33.31 
V β 5.2 24.45 15.24 20,89 13.84 22.74 14.07 22.15 25.03 44.95 20.61 
V β 6.1 31.91 25.39 9.03 25.68 43.56 30.36 69.22 22.48 29.75 26.26 
V β 6.4 37.02 15.85 1.61 20.52 58.72 7.59 58.51 23.13 35.67 30.17 
V β 6.5 34.54 29.51 22.56 26.13 31.67 20.5 52.74 35.58 31.6 26.42 
V β 7 25.3 20.99 14.79 31.40 53.19 12.11 68.15 20.86 69.94 35.02 
V β 8 90.25 38.3 21.25 29.50 44.77 38.44 45.33 52.02 31.24 52.71 
V β 9 34.99 46.19 29.17 49.50 30.27 38.42 53.27 40.85 41.7 79.65 
V β 11 15.05 48.72 6.98 24.51 26.31 19.93 37.26 16.68 13.22 30.68 
V β 12.1 22.55 35.36 8.31 26.64 55.12 64.6 54.89 33.53 15.39 60.69 
V β 12.2 21.31 28.01 18.17 26.88 52.34 53.14 29.15 29.3 18.16 56.12 
V β 13.1 33.19 53.14 12.06 25.06 32.58 37.31 36.32 42.26 33.14 29.75 
V β 13.5 19.17 81.68 15.37 24.55 40.31 37.98 27.58 19.25 39.89 30.10 
V β 14 20.36 27.98 22.31 16.37 47.7 8.71 47.19 17.12 11.14 27.42 
V β 15 38 39.19 28.89 37.40 28.74 16.75 51.28 38.74 36.55 53.22 
V β 16 43.24 31.2 19.58 29.42 48.45 27.35 30.23 48.81 29.41 38.24 
V β 17 23.86 37.12 33.37 21.48 33.88 22.38 62.68 24.72 20.65 25.56 
V β 18 31.75 29.64 13.6 43.65 37.75 22.21 46.74 54.12 26.65 51.13 
V β 21 45.68 34.88 20.83 30.28 27.39 12.3 52.2 32.01 13.78 47.57 
V β 22 26.64 27.81 18.12 31.71 33.11 20.72 39.92 47.32 28.92 31.34 
V β 23 51.24 66.22 28.2 49.10 66.53 31.66 71.74 56.38 26.06 29.23 
V β 24 48.33 43.24 20.48 47.50 78.53 25.73 50.3 48.38 31.55 47.63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4. Disscussion 
Because we and others have shown that the T-cell activation in
CVID concerned mostly the CD8 + T-compartment [ 5 , 16 , 17 ], we fo-
cused our attention on its TCR diversity. We used the immunoscope
approach, which allowed for a global estimation of the T-cell reper-
toire and represented a highly sensitive detection of overrepresented
T-cell populations. We showed that CVID patients, notably those with
complications, exhibited oligoclonal expansions in their CD8 + T-cells.
These observations were not the result of an acute clinical infectious
event, but reﬂected a stable phenotypic T-cell pattern as the CD8 + 
T-cell activation was consistently observed along six years indepen-
dently of clinical status. However, we could not establish any rela-
tionship between repertoire bias and the clinical manifestations seen
in these patients. 
There is a natural accumulation of clonal populations in CD8 + 
T-cells in aging [ 18 , 19 ], which could be related to subclinical viral
infection [ 20 ]. The CD8 + T-cells expansion seems closely associated
with cytomegalovirus (CMV) infection which is a potent immunogen
and during aging a progressive accumulation of CMV-speciﬁc T-cells
is observed which can reach until 25% or more of the CD8 + pool [ 21 –
23 ]. CMV DNA is frequently detected in the urine of elderly subjects
[ 24 ]. It is speculated that this speciﬁc T-cell expansion could inhibit
the function of other antigen-speciﬁc T-cell populations. We cannot
exclude the role of the age in the T-cells expansions of our patients,
but the age cannot alone explain the overall activation of the T-cell
compartment because oligoclonal expansion of CD8 + T cells is also
observed in young patients (patients 2, 4 and 9). 
However, a chronic viral replication, generated by the immunode-
pression, and leading to a constriction of the T-cell repertoire could
be involved in CVID patients as suggested by recent ﬁndings reported
in patients with chronic lymphocytic leukemia (CLL), another disease
also characterized by hypogammaglobulinemia. CMV-speciﬁc CD4 + 
and CD8 + T-cell populations are both increased in CMV-seropositive
CLL patients [ 25 , 26 ]. Recently, Pourgheysari et al. speculated that the
immunosuppression associated with CLL triggered a CMV reactiva-
tion that in turn activated and expanded CMV-speciﬁc T-cells [ 26 ].
They showed in CMV-seropositive CLL patients an increment in CD3 + and CD8 + T-cell counts and a marked expansion of CMV-speciﬁc
CD4 + T-cells which was more pronounced in patients who received
chemotherapy. CMV reactivation was not detected by PCR in the blood
of CLL patients suggesting that the viral replication was controlled
by the immune response. The authors suggest that such expanded
T-cell populations could have negative consequences for immunity
with a constriction of the T-cell repertoire leading to a loss of cer-
tain essential memory T-cell populations directed towards another
micro-organisms. This could explain the frequent resurgence of Vari-
cella zoster virus (VZV) infections in CLL patients. In the same way,
we could hypothesize an identical model in CVID, the humoral defect
favoring a chronic viral replication which in turns could induce T-cells
expansions. From our study, the T-cell activation was correlated with
the importance of the humoral defect. However, we did not detect
CMV in the blood of our patients by PCR, but CMV DNA has been de-
tected in the urine in older CMV-seropositive subjects and then the
detection of CMV DNA in the urine of CVID patients should be de-
termined. Moreover, conversely to CLL patients, CVID patients do not
exhibit VZV infections. Several CVID patients do not have any T-cell
activation whereas they exhibit a profound hypogammaglobulinemia
(patient 7 for example). At least, multiple CD8 + T-cell expansions
were found in CVID patients, suggesting that these cells might target
several antigens. The T cell expansions identiﬁed in this study dif-
fered from one patient to another but two selected BV families (V2
and V5.1) were more represented in the group with complications.
Detection of CMV-speciﬁc CD4 + T cells should be determined in CVID
patients to precise the role of the virus in the contraction of the T-cell
repertoire. 
The inﬂuence of IVIG substitution on T-cell activation can also be
suggested. However, the patient 3 did not receive intravenous im-
munoglobulins replacement and this patient presented a contracted
T-cell repertoire. 
Finally, the perturbations of the T-cell repertoire were particu-
larly restricted to the group of CVID patients with auto-immune and /
or organomegaly complications which suggested a link between the
mechanisms leading to the CD8 TCR repertoire restriction and those
leading to the complications in these patients, but viral reactivation
might not be the sole explanation. Usually, auto-antibodies are not
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linemia but this does not eliminate the participation of T-cells in the 
uto-immune response in these patients as a cause for their activa- 
ion. 
In summary, CVID patients exhibit a contraction of their CD8 + 
-cell repertoire whose causes remain to be deciphered but which 
re likely multifactorial. In this regard, the exploration of their CMV 
mmune statuses may be of interest for their management on the long 
erm as suggested by Marashi et al. [ 27 ]. 
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